Navigation Links
Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Date:4/1/2009

LONDON and SAN DIEGO, April 2, 2009 University College London Business PLC (UCLB) and Ocera Therapeutics Inc., a privately held biopharmaceutical company, announced the signing of an exclusive worldwide licensing agreement for UCL-L1V and all assets and technologies related to the compound for the treatment of acute hepatic encephalopathy (AHE).

The compound recently demonstrated that it directly reduces blood levels of ammonia, a highly toxic chemical that builds up during attacks of AHE.

Ocera will develop the licensed compound as its second pipeline compound and refer to it as OCR-002. OCR-002 is a novel injectable for the treatment of AHE in patients with advanced liver cirrhosis and acute liver failure.

The licensing agreement is based on research conducted by the collaborative global research project led by Professor Rajiv Jalan and the Liver Failure Group at the Institute of Hepatology, UCL (University College London). The research includes a study which demonstrated an acute and sustained reduction of systemic ammonia levels as well as decreased intracranial pressure in models of AHE in acute liver failure and cirrhosis. The data was published online in Hepatology in February 2009.

Clinical trials in patients with AHE due to cirrhosis and acute liver failure will be carried out at University College Hospital as well as other centres in 2009 under funding from the Medical Research Council (MRC) in the U.K. Ocera is planning to file an IND in late 2009 and U.S. trials will begin in early 2010.

AHE is a reversible neuropsychiatric abnormality frequently seen as a complication of acute liver failure and cirrhosis. With severe liver impairment, toxic substances such as ammonia that are normally removed by the liver accumulate in the blood and impair the function of brain cells.

Signs of AHE include impaired cognition, uncontrolled movements and decreased levels of consciousness leading to coma.

Cirrhosis, which can cause AHE, occurs due to a variety of causes such as hepatitis B and C infection, alcohol, and fatty liver associated with obesity and diabetes. It is estimated that there are up to 1 million cirrhosis patients in the U.S. Acute liver failure is a life threatening condition in otherwise healthy patients and is most commonly caused by an overdose of paracetamol (acetaminophen in the U.S.).

Other causes include reactions to other drugs, herbs, or acute hepatitis. AHE is one of the common complications of cirrhosis and acute liver failure, and up to150,000 patients are hospitalised in the U.S. each year.

"We are pleased to have licensed this breakthrough treatment for patients hospitalised with acute hepatic encephalopathy," said Dr. Laurent Fischer, President and CEO of Ocera Therapeutics. "By directly reducing blood levels of ammonia, OCR-002 has the potential not only to improve symptoms of encephalopathy but may also help to reverse this life-threatening condition and reduce healthcare costs by minimising a patient's time in intensive care."

"There is a significant unmet clinical need to treat hepatic encephalopathy which affects 40-60 percent of patients with established liver disease," stated Professor Rajiv Jalan M.D. "Unlike UCL-L1V, none of the currently available treatments directly lowers circulating levels of ammonia. The partnership with Ocera is a significant step towards bringing this potentially lifesaving discovery to patients."

Mr. Cengiz Tarhan, Managing Director of UCLB said, "This is a significant deal for UCL Business. I am delighted that Ocera is licensing the technology from us. In Ocera, we have found the perfect development and commercialisation partner. They specialise in liver and gastrointestinal drug development and have a demonstrated track record. I am excited to enter this relationship to tap into their extensive experience to bring this technology to market."


'/>"/>

Contact: Ruth Metcalfe
r.metcalfe@gmail.com
44-020-767-99739
University College London
Source:Eurekalert

Related biology news :

1. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
2. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
3. A novel target for therapeutics against Staph infection
4. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
5. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
6. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
7. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
8. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
9. Michael J. Fox Foundation PD Therapeutics Conference
10. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
11. Syntermed licenses Emory ERTb software for enhanced cardiac imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/28/2016)... , Nov. 28, 2016 ... a rate of 16.79%" The biometric system market ... grow further in the near future. The biometric system ... billion in 2022, at a CAGR of 16.79% between ... system, integration of biometric technology in smartphones, rising use ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... 2016  SRI International has been awarded a ... National Institutes of Health,s National Institute of Allergy ... (NIAID-DAIDS) to support the manufacturing and characterization of ... Under the seven-year contract, SRI will provide a ... candidate HIV-prevention products that emerge from investigator-initiated studies ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... cellulose nanocrystals and cellulose nanofibrils. The composition claims are not limited to ... claims directed to combination with polymers, carbon fibers, graphene, and other materials. ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, a ... heart failure and other chronic diseases, announced that ... company as Chief Financial Officer (CFO), effective today. ... 20 years of experience in financial management for ... and software companies. Most recently, Ms. Bovenizer was ...
(Date:12/5/2016)... YORK , December 5, 2016 ... player worldwide, with almost $108 billion of revenue and ... $170 billion were spent on global biopharmaceuticals, and this ... This morning, Stock-Callers.com has lined up these four equities ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ...
Breaking Biology Technology: